Wellington Management Group LLP Trims Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Wellington Management Group LLP trimmed its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 17.4% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 89,057 shares of the biotechnology company’s stock after selling 18,763 shares during the period. Wellington Management Group LLP’s holdings in BioCryst Pharmaceuticals were worth $670,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the period. Hillsdale Investment Management Inc. increased its stake in BioCryst Pharmaceuticals by 65,213.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock worth $4,077,000 after buying an additional 541,270 shares during the period. Norges Bank acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $3,947,000. Schroder Investment Management Group boosted its position in BioCryst Pharmaceuticals by 523.9% in the 4th quarter. Schroder Investment Management Group now owns 522,657 shares of the biotechnology company’s stock valued at $3,936,000 after buying an additional 438,887 shares during the period. Finally, Principal Financial Group Inc. grew its stake in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Ratings Changes

BCRX has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI increased their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday. JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $7.04 on Tuesday. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.50. The firm has a fifty day moving average of $7.93 and a two-hundred day moving average of $7.74. The company has a market cap of $1.47 billion, a P/E ratio of -11.54 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. The business’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.